09811nas a2200289   4500008004500000022001400045245013900059210006900198260002100267300000700288490000700295520886400302653002309166653003209189653003609221653002209257653002709279653002509306100001809331700002309349700002009372700001909392700001809411700002309429700002009452856004909472       2012                        Engldsh    a0902-006300aThe impact of hepatitis C virus donor and recipient status on long-term kidney transplant outcomes: University of Wisconsin experience0 aimpact of hepatitis C virus donor and recipient status on longte  cSeptember/Octobe  a840 v263 a: The survival benefit of transplanting hepatitis C (HCV)-positive donor kidneys into HCV-positive recipients remains uncertain. The purpose of this study was to assess the effect of HCV-status of the donor (D) kidney on the long-term outcomes in kidney transplant recipients (R). We evaluated 2169 consecutive recipients of deceased-donor kidney transplants performed between 1991 and 2007. The following HCV cohorts were identified: D-/R- (n = 1897), D-/R+ (n = 59), D+/R- (n = 118), and D+/R+ (n = 95). Patients were followed for a mean of 6.02 (standard deviation = 4.26) yr. In a mulitvariable Cox-proportional hazards model, D+/R+ cohort had significantly lower patient survival (adjusted-hazard ratio [HR] 2.1, 95% CI [1.4-2.9]) with respect to the reference D-/R- group, whereas mortality was not increased in D-/R+ group. The rate of graft loss was increased in both D+/R+ and D-/R+ but was comparable with each other (adjusted-HR 1.8, 95% CI [1.4-2.5]) vs. adjusted-HR 2.0, 95% CI [1.4-2.8], respectively). D-/R+ cohort experienced significantly higher rate of rejection (adjusted-HR 1.7, 95% CI [1.2-2.5]) and chronic allograft nephropathy (adjusted-HR 2.1, 95% CI [1.2-3.7]). Neither donor nor recipient HCV-status impacted the risk of recurrent or de novo GN. Transplanting HCV-positive kidneys as opposed to HCV-negative kidneys into HCV-positive recipients provided similar graft survival but compromised patient survival in the long term. Copyright (C) 2012 Blackwell Publishing Ltd.; References: 1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989: 244: 359. 2. Kuo G, Choo QL, Alter HJ. et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989: 244: 362. 3. Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992: 15: 350. 4. Pereira BJ, Milford EL, Kirkman RL, Levey AS. Transmission of hepatitis C virus by organ transplantation. N Engl J Med 1991: 325: 454. 5. Gomez E, Aguado S, Gago E. et al. A study of renal transplants obtained from anti-HCV positive donors. Transplant Proc 1991: 23: 2654. 6. Roth D, Fernandez JA, Babischkin S. et al. Detection of hepatitis C virus infection among cadaver organ donors: evidence for low transmission of disease. Ann Intern Med 1992: 117: 470. 7. Triolo G, Squiccimarro G, Baldi M. et al. Antibodies to hepatitis C virus in kidney transplantation. Nephron 1992: 61: 276. 8. Mizrahi S, Hussey JL, Hayes DH, Boudreaux JP. Organ transplantation and hepatitis C virus infection. Lancet 1991: 337: 1100. 9. Diethelm AG, Roth D, Ferguson RM. et al. Transmission of HCV by organ transplantation. N Engl J Med 1992: 326: 410, author reply 2-3. 10. Pirsch JD, Belzer FO. Transmission of HCV by organ transplantation. N Engl J Med 1992: 326: 412, author reply 3. 11. Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995: 345: 484. 12. Bouthot BA, Murthy BV, Schmid CH, Levey AS, Pereira BJ. Long-term follow-up of hepatitis C virus infection among organ transplant recipients: implications for policies on organ procurement. Transplantation 1997: 63: 849. 13. Morales JM, Campistol JM, Castellano G. et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int 1995: 47: 236. 14. Pirsch JD, Heisey D, D' Allesandro AM, Knechtle SJ, Sollinger HW, Belzer FO. Transplantation of hepatitis C (HCV) kidneys: defining the risks. 14th Annual Meeting of the American Society of Transplant Physicians, May 14-17, 1995, Chicago, IL. 15. Abbott KC, Bucci JR, Matsumoto CS. et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol 2003: 14: 2908. 16. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004: 4: 2032. 17. Ali MK, Light JA, Barhyte DY. et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation. Transplantation 1998: 66: 1694. 18. Kucirka LM, Singer AL, Ros RL, Montgomery RA, Dagher NN, Segev DL. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant 2010: 10: 1238. 19. Morales JM, Campistol JM, Dominguez-Gil B. et al. Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. Am J Transplant 2010: 10: 2453. 20. Pereira BJ, Wright TL, Schmid CH. et al. Screening and confirmatory testing of cadaver organ donors for hepatitis C virus infection: a U.S. National Collaborative Study. Kidney Int 1994: 46: 886. 21. Bucci JR, Matsumoto CS, Swanson SJ. et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002: 13: 2974. 22. Schnitzler MA, Craig KE, Hardinger KE, Lowell JA, Brennan DC. Mycophenolate mofetil is associated with less death with function than azathioprine in cadaveric renal transplantation. Nephrol Dial Transplant 2003: 18: 1197. 23. Bucci JR, Lentine KL, Agodoa LY, Peters TG, Schnitzler MA, Abbott KC. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl, 2004: 51. 24. Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005: 5: 139. 25. Mandal AK, Kraus ES, Samaniego M. et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin Transplant 2000: 14: 391. 26. Mathurin P, Mouquet C, Poynard T. et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999: 29: 257. 27. Stock PG. Balancing multiple and conflicting allocation goals: a logical path forward. Am J Transplant 2009: 9: 1519. 28. Nampoory MR, Johny KV, Costandi JN. et al. High incidence of proteinuria in hepatitis C virus-infected renal transplant recipients is associated with poor patient and graft outcome. Transplant Proc 2001: 33: 2791. 29. Gentil MA, Rocha JL, Rodriguez-Algarra G. et al. Impaired kidney transplant survival in patients with antibodies to hepatitis C virus. Nephrol Dial Transplant 1999: 14: 2455. 30. Cosio FG, Roche Z, Agarwal A, Falkenhain ME, Sedmak DD, Ferguson RM. Prevalence of hepatitis C in patients with idiopathic glomerulopathies in native and transplant kidneys. Am J Kidney Dis 1996: 28: 752. 31. Cruzado JM, Carrera M, Torras J, Grinyo JM. Hepatitis C virus infection and de novo glomerular lesions in renal allografts. Am J Transplant 2001: 1: 171. 32. Brunkhorst R, Kliem V, Koch KM. Recurrence of membranoproliferative glomerulonephritis after renal transplantation in a patient with chronic hepatitis C. Nephron 1996: 72: 465. 33. Roccatello D, Fornasieri A, Giachino O. et al. Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis. Am J Kidney Dis 2007: 49: 69. 34. Roth D, Cirocco R, Zucker K. et al. De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients. Transplantation 1995: 59: 1676. 35. Hammoud H, Haem J, Laurent B. et al. Glomerular disease during HCV infection in renal transplantation. Nephrol Dial Transplant 1996: 11(Suppl 4): 54. 36. Aroldi A, Lampertico P, Montagnino G. et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 2005: 79: 1132. 37. Hanafusa T, Ichikawa Y, Kishikawa H. et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998: 66: 471. 38. Zylberberg H, Nalpas B, Carnot F. et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002: 17: 129. 39. Legendre C, Garrigue V, Le Bihan C. et al. Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998: 65: 667. 40. Aroldi A, Lampertico P, Elli A. et al. Long-term evolution of anti-HCV-positive renal transplant recipients. Transplant Proc 1998: 30: 2076. 41. National Kidney Foundation. KDIGO. Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008: 73: S1.10aClinical Medicine.10ahepatitis C positive donors10ahepatitis C positive recipients10ahepatitis C virus10aKidney Transplantation10atransplant outcomes.1 aSingh, Neeraj1 aNeidlinger, Nikole1 aDjamali, Arjang1 aLeverson, Glen1 aVoss, Barbara1 aSollinger, Hans, W1 aPirsch, John, D  uhttps://www.notifylibrary.org/reference/1827